[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-445579-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-445579-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pd46-efficacy-and-safety-of-scalp-inflammation-treatment-in-patients-with-seborrheic-dermatitis-an-overview-of-systematic-reviews","PD46 Efficacy And Safety Of Scalp Inflammation Treatment In Patients With Seborrheic Dermatitis: An Overview Of Systematic Reviews","","Scalp seborrheic dermatitis is a chronic inflammatory condition treated with options including antifungal shampoos, corticosteroids, calcineurin inhibitors, and phototherapy. A systematic review was conducted to evaluate the efficacy, safety, and evidence certainty of topical and oral treatments for SSD, supporting health technology assessment for improved clinical and resource decisions. Eight systematic reviews (80 studies) were included, showing moderate evidence for ketoconazole shampoo and ciclopirox gel and low or very low evidence for many commonly used alternatives.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pd46-efficacy-and-safety-of-scalp-inflammation-treatment-in-patients-with-seborrheic-dermatitis-an-overview-of-systematic-reviews/445579/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pd46-efficacy-and-safety-of-scalp-inflammation-treatment-in-patients-with-seborrheic-dermatitis-an-overview-of-systematic-reviews/445579.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What treatments were considered for scalp seborrheic dermatitis (SSD)?","Question",{"text":63,"@type":64},"Topical and oral treatments were evaluated, including antifungal shampoos, corticosteroids, calcineurin inhibitors, and phototherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was evidence certainty assessed in the review?",{"text":68,"@type":64},"Evidence certainty for efficacy and safety outcomes was assessed using GRADE or the Oxford Centre for Evidence-Based Medicine, with risk of bias evaluated using the AMSTAR tool.",{"name":70,"@type":61,"acceptedAnswer":71},"Which treatments showed moderate evidence for symptom reduction?",{"text":72,"@type":64},"Ketoconazole shampoo (2% to 7%) and ciclopirox gel (0.77% to 1.0%) had moderate certainty evidence for symptom reduction.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},445579,1790832607,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":22,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":30,"preview_page_count":4},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","S58 Poster Presentations (online)  \nspecialists from the Spanish Network of Agencies for Health Technology Assessment (RedETS) .  \nResults: The scoping review for ELSO issues in genetic testing for cHL identified 452 references. After eligibility assessment, four reports were included, providing eight ELSO issues: two organizational, two social, and four ethical. Six concerns were facilitators and two were barriers to implementing genetic testing in cHL. The scoping review for ELSO issues in the MITS to determine cause of death identified903references. After eligibility assessment,25reports were included, bringing forth 43 ELSO concerns: 18 organizational, 15 social, seven ethical, and three legal. Twenty-three issues were facilitators and 20 may be barriers to implementing MITS. Conclusions: The analysis of ELSO domains through a scoping review provided crucial information for implementing the two selected technologies. However, challenges remain in ELSO information retrieval: (i) key concepts related to ELSO concerns could be described in a variety of ways; and (ii) ELSO terms are not being used or indexed consistently.  \nPD46 Efficacy And Safety Of Scalp Inflammation Treatment In Patients With Seborrheic Dermatitis: An Overview Of Systematic Reviews  \nMayra Kaizer ([lemoshealth@gmail.com](lemoshealth@gmail.com)), Thays de Andrade Apolinário and Jamilly Pereira de Almeida  \nIntroduction: Scalp seborrheic dermatitis (SSD) is a chronic inflammatory condition with various treatment options, including antifungal shampoos, corticosteroids, calcineurin inhibitors, and phototherapy. This study aimed to evaluate the efficacy, safety, and evidence certainty of topical and oral treatments for SSD, highlighting the importance of this research for health technology assessment (HTA) to guide healthcare decisions and optimize resource utilization.  \nMethods: A systematic review (PROSPERO CRD42024537759) was conducted by searching PubMed, the Cochrane Library, and Embase databases through to 18 April 2024, using descriptors and terms related to SSD and study design. Systematic reviews evaluating evidence certainty (GRADE or Oxford Centre for Evidence-Based Medicine) for efficacy and safety outcomes of SSD treatments were included. Data selection and extraction were independently performed by two reviewers, and the risk of bias was assessed using the AMSTAR tool. A qualitative synthesis of the results was conducted. Results: Eight systematic reviews (80 studies on SSD) were included. Evidence quality supporting topical and oral treatments for SSD varied significantly. Ketoconazole shampoo (2 to 7%; 30 studies) and ciclopirox gel (0.77 to 1.0%; 16 studies) were the most frequently studied treatments and had moderate certainty of evidence for symptom reduction, as they were assessed in better designed studies. In contrast, other treatments commonly used in daily clinical practice were graded as having low-quality evidence (e.g., bifonazole  \nshampoo, selenium sulfide shampoo, coal tar-ciclopirox olamine combination, gluconate ointment, succinate ointment) or very lowquality evidence according to GRADE (e.g., clobetasol propionate shampoo, zinc pyrithione shampoo, hydrocortisone) .  \nConclusions: The review highlighted significant variability in evidence quality for SSD treatments. While ketoconazole shampoo and ciclopirox gel showed moderate evidence for symptom reduction, many commonly used treatments were supported by low or very low quality evidence. These findings underscore the importance of rigorous studies to inform HTA and support evidence-based decisionmaking in health care.  \nPD47 Procurement Of Human Polyvalent Immunoglobulins: A Tender Analysis In Europe  \nJonathan Galduf ([jonathan.galduf@cslbehring.com](jonathan.galduf@cslbehring.com)), Carla Bellver, Laurie Marlow, Jie Shen and Nicholas Redman  \nIntroduction: Human polyvalent immunoglobulins (Igs) are plasma-derived medicinal products that are used to treat a range of condition","cbCaiqgkNkrr3dfy","https://ap.wps.com/l/cbCaiqgkNkrr3dfy","pdf",30140,"English","# PD46 Efficacy And Safety Of Scalp Inflammation Treatment In Patients With Seborrheic Dermatitis: An Overview Of Systematic Reviews\n## Introduction\n## Methods\n## Results\n## Conclusions","[{\"question\":\"What treatments were considered for scalp seborrheic dermatitis (SSD)?\",\"answer\":\"Topical and oral treatments were evaluated, including antifungal shampoos, corticosteroids, calcineurin inhibitors, and phototherapy.\"},{\"question\":\"How was evidence certainty assessed in the review?\",\"answer\":\"Evidence certainty for efficacy and safety outcomes was assessed using GRADE or the Oxford Centre for Evidence-Based Medicine, with risk of bias evaluated using the AMSTAR tool.\"},{\"question\":\"Which treatments showed moderate evidence for symptom reduction?\",\"answer\":\"Ketoconazole shampoo (2% to 7%) and ciclopirox gel (0.77% to 1.0%) had moderate certainty evidence for symptom reduction.\"}]","PD46 Efficacy And Safety Of Scalp Inflammation Treatment In Patients With Seborrheic Dermatitis: An Overview Of Systematic Reviews | PDF",1790712418]